SecBot SecBot
DEF 14A ·Filed Oct 23, 2026

MRAI

Marpai, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4d 7h ago SEC0001213900-26-112160
Definitive proxy statement
Actionable Insight ▼ Bearish

The proxy reveals a micro-cap sustained entirely by insider financing from the CEO's affiliated entity (HillCour) and insider loans. The departure of two presidents in under two years and the CEO's $1 salary with massive stock grants suggest a founder-led entity with minimal independent oversight. Monitor for any going-concern language in the next 10-K and for further insider-led capital raises, as the company's cash runway absent related-party support is unclear.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+1d
MRAI ▼ -0.64% at T+1d
SHORT call ✓ call won +0.64% · α vs SPY +1.15% · entry $3.11 → $3.09
Next anchor: T+5d in 2d
Entry = T+0 close
Oct 23, 2026
via day close
T+1d
-0.64%
call +0.64% · α +1.15%
$3.09
settled yesterday
T+5d
Pending
in 2d
T+20d
Pending
in 23d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Marpai, Inc. filed its definitive proxy statement for the 2026 annual meeting, proposing the election of five directors (excluding Sagiv Shiv who declined re-nomination) and ratification of UHY LLP as auditor. The filing reveals a deeply distressed micro-cap: CEO Damien Lamendola received $1.2M in stock-based compensation in 2025 (up from $362K in 2024) despite a net loss of $13.6M and a negative total shareholder return. The company has relied heavily on related-party private placements from HillCour (controlled by the CEO) and insider loans to fund operations, with CEO promissory notes totaling $660K in early 2026 that were later repaid. Director and executive officer group owns 46.9% of shares, and the company is not listed on a national securities exchange.

Key Facts

  • CEO Damien Lamendola received $1,206,000 in total compensation for FY2025, entirely in stock awards, up from $362,000 in FY2024.
  • Net loss improved to $13.6M in FY2025 from $22.1M in FY2024, but the company remains deeply unprofitable.
  • Cumulative total shareholder return (TSR) was $18.96 on a $100 investment over two years, down from $24.64 at end of FY2024.
  • Director Sagiv Shiv is not standing for re-election; the board will shrink from six to five members.
  • The company issued $660,000 in promissory notes to CEO Damien Lamendola in Feb-Mar 2026, which were fully repaid by June 22, 2026.
  • HillCour (controlled by CEO Lamendola) participated in multiple private placements in 2024-2025, purchasing shares at prices from $0.481 to $1.36 per share.
  • Directors and executive officers as a group beneficially own 46.9% of outstanding common stock.
  • Audit fees for FY2025 were $441,000, down from $538,000 in FY2024.
  • The company is not currently listed on a national securities exchange.
  • Two presidents/COOs (John Powers and Dallas Scrip) resigned in 2025-2026, with Scrip serving only ~8 months.

Financial Impact

CEO compensation of $1.2M in stock awards against a $13.6M net loss; related-party financings of undisclosed aggregate amount; $660K in CEO promissory notes repaid in 2026

compensationnet incomeshareholder returnrelated party transactions

Risk Factors

  • Going-concern risk: sustained net losses ($13.6M in FY2025) and reliance on related-party financing from HillCour/CEO
  • Governance risk: CEO controls 32.5% of shares via HillCour entities; board has high insider representation
  • Compensation misalignment: CEO received $1.2M in stock awards despite negative TSR and $13.6M net loss
  • Key person risk: two presidents resigned within 8 months; CEO is 71 years old
  • Liquidity risk: company is not listed on a national securities exchange, limiting access to public equity markets

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001213900-26-112160
Document: 0001213900-26-112160-index-headers.html0001213900-26-112160
Document: 0001213900-26-112160-index.html0001213900-26-112160
Document: 0001213900-26-112160.txt0001213900-26-112160
3 reports for MRAI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MRAI — sortable, filterable
TypeNow
Oct 23, 2026
4d ago
DEF 14A
BEARISH ★ 5/10
$3.11 $3.09▲ +0.64%▲ +1.15%$3.04 (+2.32%)
Jul 31, 2026
12w ago
8-K
BEARISH ★ 6/10
$2.15 $2.20▼ −2.33%▼ −0.52%$3.04 (−41.30%)
Jul 20, 2026
14w ago
8-K
BULLISH ★ 6/10
$1.70 $1.87▲ +10.00%▲ +10.12%$3.04 (+78.71%)
Showing 3 of 3

US Market Status

Market Closed — Opens Thu (9h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 23, 2026